$RGRX Another link to an article:
HLB Chairman Jin Yang-gon Purchases Additional Shares of HLB Therapeutics and HLB Genex
https://www.fntimes.com/html/view.php?ud=202606021602351123923defd0cc_18
Quotes:
-Following his purchase of 10,974 shares of HLB Therapeutics on the 29th of last month, Chairman Jin bought an additional 25,000 shares on the 1st of this month.
-As a result, Chairman Jin’s stock holdings increased to 291,692 shares of HLB Therapeutics
-HLB Therapeutics is also scheduled to disclose the top-line results of its Phase 3 (SEER-2) clinical trial for 'RGN-259,' a candidate treatment for neurotrophic keratitis (NK).
-"We will focus on enhancing the overall corporate value of the group by actively communicating to the market the approval events for key pipelines starting in July and the growth strategies of each affiliate."
NOW CONSIDER THIS:
Both g-tree and hlb thera always stated they would License Out the TB4 Eye…
THUS: TB4 EYE license out it quickest way to float the HLB BOAT…
Enjoy the read,
THE DONKER
$RGRX HLB Chairman Jin Yang-gon Makes Additional Open Market Purchases of HLB Therapeutics and HLB Genex Shares
https://www.newspim.com/news/view/2026060200057
Quote
HLB Therapeutics is also scheduled to release top-line results from the Phase 3 clinical trial (SEER-2) of its neurotrophic keratitis (NK) treatment candidate, 'RGN-259
Jin bought quite a bit of shares lately and in the last year.
THE DONKEr
$RGRX HLB Thera 2965 breached so the only way we don't head further down is a leading diagonal which are uncommon but possible. A cluster of corrective waves since October. This is my best guess - a move down to finally finish off the bear. Since black 4 was an irregular wave all the count needs is a close below 2638. Probably make a new low but doesn't have to. Tricky chart.
$RGRX Two things need to happen for HLB Thera's chart to stay impulsive. 1) Needs to head up now. 3090 was Friday close and overlap of blue 1 - 3070 close) -would likely turn the chart bearish. Absolute line in the sand is a close below 2965. 2) needs to eclipse April high close of 3980 before end of May. So bottom line - Needs to move up now and move up strong.
$RGRX HERE’S why BIG PHARMA will get TB4 EYE rights:
BIG PHARMA plans years ahead…
(TB4 holy $$ grail):
Wayne State and TB4/VIP
https://research.wayne.edu/news/wayne-state-university-research-aims-to-reduce-diabetes-effect-on-vision-66357
https://pmc.ncbi.nlm.nih.gov/articles/PMC10669755/#sec4-biosensors-13-00974
Despite the prevalence of diabetic retinopathy, up to 70% of the 460+ million diagnosed diabetics worldwide present with signs of diabetic corneal complications
HUGE MARKET
TB4/VIP COMBO Grant in 2nd year:
https://reporter.nih.gov/search/z7kwVkQAgkqkpsWD0HiBeA/project-details/11312728
The global diabetic eye disease market is experiencing significant growth, driven by an increasing prevalence of diabetes, an aging global population, and advancements in diagnostic and treatment technologies. The market is projected to grow from approximately USD 9.5 billion in 2024 to over USD 13.77 billion by 2030, growing at a CAGR of roughly 6.4% to 8.5%
THE DONKER
$RGRX Might want to read the following article:
https://www.eyeworld.org/2026/early-momentum-in-biologics-for-corneal-conditions/
Chamberlain: ReGenTree site investigator
Pflugfelder: ***NOTE*** historically has been a LONG TERM ADVOCATE for TB4 EYE
-do a little research on this!!!
ENJOY the read,
THE DONK
$RGRX HLB Thera - time to head up again. Blue Minor wave 4 looks complete with a .618 retrace after the big move up. Using bar chart to show the retrace. There should be 3 more large waves up to complete the sequence.
$RGRX Anyone heard anything from the bunker in New Jersey? Radio silence on all fronts. Not even an update to shareholders...even a "no news" update would be appreciated.
$RGRX HLB Therapeutics also aims to announce the top-line results of the global Phase 3 clinical trial for ' RGN-259, ' a treatment for neurotrophic keratitis ( NK ) currently under development through its subsidiary Regentry , this coming June.
HLB Group Chairman Jin Yang-gon Purchases Affiliate Stocks 16 Times This Year
